An announcement from Zhejiang Hisun Pharmaceutical Co.,Ltd. (ASX: 600267) indicates that the company has recently obtained the "Chemical Drug Substance Marketing Authorization Approval Notice" for letermovir from the National Medical Products Administration.
The approved drug substance, letermovir, is indicated for the prevention of cytomegalovirus (CMV) infection and CMV disease in CMV-seropositive adult recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT), as well as in pediatric recipients aged 6 months and older weighing ≥6 kg.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments